STOCK TITAN

Adverum Biotechnologies, Inc. - $ADVM STOCK NEWS

Welcome to our dedicated page for Adverum Biotechnologies news (Ticker: $ADVM), a resource for investors and traders seeking the latest updates and insights on Adverum Biotechnologies stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adverum Biotechnologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adverum Biotechnologies's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.46%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.85%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.04%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.43%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.81%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
management
Adverum Biotechnologies, Inc.

Nasdaq:ADVM

ADVM Rankings

ADVM Stock Data

216.47M
11.72M
0.91%
80.01%
4.29%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
REDWOOD CITY

About ADVM

adverum (nasdaq: advm) is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. we are advancing the development of a robust pipeline of gene therapies that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (a1at) deficiency and hereditary angioedema (hae) as well as wet age-related macular degeneration (wamd). leveraging our next-generation adeno-associated virus (aav)-based directed evolution platform, we generate gene therapies designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.